D3 Bio announced the completion of a USD 108 million Series B financing round. The funding round was backed by IDG Capital and SongQing Capital. Existing investors — WuXi AppTec's Corporate Venture Fund, Temasek, HSG, MPCi and Medicxi — also contributed to the round. 

Proceeds from this financing will support the planned global Phase III pivotal programme for the company's lead asset, elisrasib (D3S-001). These pivotal trials will assess elisrasib as both a monotherapy and in combination therapies for KRAS G12C-mutant cancers across key countries and regions, including the United States, China and the European Union (EU), to facilitate global regulatory submissions.

Dr George Chen, Founder, Chairman, and CEO, D3 Bio, stated, "The completion of our Series B financing demonstrates the strong confidence our investors place in our vision, scientific approach, business operations and global development capabilities. This funding enables us to advance our lead programme into late-stage clinical trials and further expand our pipeline of innovative therapies designed to benefit patients globally."

Furthermore, the funding will facilitate ongoing development of D3 Bio's comprehensive pipeline of targeted and immuno-oncology programmes, which are centred on innovative mechanisms with the first-in-class or the best-in-class potential.

Dr Antoine Yver, Member—Board of Directors and Scientific Committee, D3 Bio, stated, "This financing demonstrates that the swift and effective pursuit of the best- or first-in-class science is meaningful to society, and validates D3 Bio's leading innovation, scientific vision and development strategy. It also highlights the unique potential of elisrasib for individuals affected by KRAS G12C-mutant cancers."